Completed PHASE4 INTERVENTIONAL NCT00317486

Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Sponsor: Actelion

Conditions Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Interventions bosentan

Updated 7 times since 2017 Last updated: Jan 31, 2025 Started: Sep 30, 2003 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00317486, this PHASE4 trial focuses on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology and remains completed. Sponsored by Actelion, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Mar 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Apr 2022 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.